Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration

Publisher： Jaypee Infomedia

E-ISSN： 0975-1947|11|1|3-7

ISSN： 0974-0333

Source： Journal of Current Glaucoma Practice, Vol.11, Iss.1, 2017-01, pp. : 3-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Case of Sustained Intraocular Pressure Elevation after Multiple Intravitreal Injection of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration

By  

Case Reports in Ophthalmology, Vol. 7, Iss. 1, 2016-04 ,pp. : 230-236

Karger

Access to resources Recommend Favorite

Anterior Chamber Paracentesis Might Prevent Sustained Intraocular Pressure Elevation after Intravitreal Injections of Ranibizumab for Age-Related Macular Degeneration

By  

Ophthalmic Research, Vol. 52, Iss. 4, 2014-11 ,pp. : 234-238

Karger

Access to resources Recommend Favorite

Optical coherence tomography-based intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

By Ernst Benjamin   Barkmeier Andrew   Akduman Levent  

International Ophthalmology, Vol. 30, Iss. 3, 2010-06 ,pp. : 267-270

Springer Publishing Company

Access to resources Recommend Favorite

Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 223, Iss. 6, 2009-07 ,pp. : 370-375

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab for Predominantly Hemorrhagic Choroidal Neovascularization in Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 233, Iss. 2, 2015-01 ,pp. : 74-81

Karger

Access to resources Recommend Favorite